News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lightlake Therapeutics Inc. (LLTP) to Develop Opioid Drug Treatment in Collaboration With the National Institute on Drug Abuse (NIDA)


4/24/2013 11:32:09 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LONDON--(BUSINESS WIRE)--Lightlake Therapeutics Inc. (OTCBB: LLTP) (the “Company”, “We” or “Lightlake”), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has signed a collaboration agreement with the Division of Pharmacotherapies and Medical Consequences of Drug Abuse (“DPMCDA”) of the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health (“NIH”), to co-develop a treatment for opioid addiction that utilizes the Company’s innovative proprietary technology.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   
Addiction

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES